The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Cryogenicists use the Kelvin or Rankine temperature scale, both of which measure from absolute zero, rather than more usual scales such as Celsius which measures from the freezing point of water at sea level or Fahrenheit which measures from the freezing point of a particular brine solution at sea level.
Oxycodone was first made available in the United States in 1939. In the 1970s, the FDA classified oxycodone as a Schedule II drug, indicating a high potential for non-medical use and addiction. After its 1995 approval by the FDA by Deputy Director Curtis Wright IV, Purdue Pharma introduced OxyContin, a controlled release formulation of oxycodone in 1996. However, drug users quickly learned how to simply crush the controlled release tablet to swallow, inhale, or inject the high-strength opioid for a powerful morphine-like high. In fact, Purdue's private testing conducted in 1995 determined that 68% of the oxycodone could be extracted from an OxyContin tablet when crushed. In 2007, Purdue paid $600 million in fines after being prosecuted for making false claims about the risk of opioid use disorder associated with oxycodone. In 2010, Purdue Pharma reformulated OxyContin, using a polymer to make the pills extremely difficult to crush or dissolve in water to reduce non-medical use of OxyContin. The FDA approved relabeling the reformulated version as abuse-resistant. OxyContin use following the 2010 reformulation declined slightly while no changes were observed in the use of other opioids. In June 2017, the FDA asked the manufacturer to remove its long-acting form of oxymorphone (Opana ER) from the US market, because the drug's benefits may no longer outweigh its risks, this being the first time the agency has asked to remove a currently marketed opioid pain medication from sale due to public health consequences of non-medical use.
Following the outbreak of the COVID-19 pandemic, the NIH-funded EcoHealth Alliance has been the subject of controversy and increased scrutiny due to its ties to the Wuhan Institute of Virology (WIV)—which has been at the center of speculation since early 2020 that SARS-CoV-2 may have escaped in a lab incident. Between 2014 and 2019, NIH awarded approximately $3.7 million in grant funding to EcoHealth Alliance, a nonprofit organization focused on global health and infectious disease research. A portion of this funding, around $600,000, was subcontracted to WIV in China as part of a project titled "Understanding the Risk of Bat Coronavirus Emergence." The project aimed to study bat coronaviruses and assess their potential to infect humans. The research at WIV included the creation of chimeric viruses, which combined genetic material from different bat coronaviruses to evaluate their ability to infect human cells. In documents released in 2021, including NIH correspondence with Congress, it was disclosed that one of these modified viruses resulted in an "unexpected outcome," where the virus became more infectious in humanized mice. The NIH maintained that this outcome was not the intended goal of the research and did not violate the terms of the grant, though critics raised concerns about potential gain-of-function research. Under political pressure, the NIH withdrew funding to EcoHealth Alliance in July 2020. In 2023, HHS barred WIV from receiving U.S. government funding for a decade, citing non-compliance with safety and reporting standards.
Most of the structures that make up animals, plants and microbes are made from four basic classes of molecules: amino acids, carbohydrates, nucleic acid and lipids (often called fats). As these molecules are vital for life, metabolic reactions either focus on making these molecules during the construction of cells and tissues, or on breaking them down and using them to obtain energy, by their digestion. These biochemicals can be joined to make polymers such as DNA and proteins, essential macromolecules of life.
== Taxonomy == Papaver somniferum was given its accepted name by the Swedish botanist Carl Linnaeus on page 508 of his Species Plantarum in 1753. It is classified in the genus Papaver within the larger family Papaveraceae. It has two accepted subspecies and one natural hybrid between them:
Sources: en.wikipedia.org
=== Clearance and signal transduction === 1. SR-A (Macrophage Scavenger Receptor Type I and II):: SR-A, also known as macrophage scavenger receptor Type I and II, is primarily expressed on macrophages. These receptors play an important role in recognizing and clearing modified proteins such as AGEs from circulation. The binding of AGEs to SR-A triggers internalization and degradation, effectively reducing oxidative stress within tissues. Upon ligand binding, SR-A activates downstream signaling pathways that promote phagocytosis and lysosomal degradation. This receptor also plays a role in modulating inflammatory signaling pathways, thereby contributing to the regulation of tissue homeostasis and preventing chronic inflammation caused by AGE accumulation. OST-48 (Oligosaccharyl Transferase-4) (AGE-R1):OST-48, commonly referred to as AGE-R1, is involved in detoxifying and preventing the accumulation of AGEs, especially under conditions such as diabetes. The expression of OST-48 is regulated by cellular stress responses, particularly oxidative stress, which often coincides with elevated AGE levels. OST-48 contributes to reducing AGE-induced cellular toxicity by facilitating the breakdown of AGEs into less harmful by-products. The receptor interacts with various signaling molecules, such as peroxisome proliferator-activated receptor gamma (PPAR-γ), which assists in mitigating cellular stress responses and restoring metabolic balance. This detoxification process plays a crucial role in limiting the negative impacts of AGEs on vascular and metabolic health.
If, for example, the Sun were replaced by a black hole of equal mass, the orbits of the planets would be essentially unaffected. Seasons are not caused by Earth being closer to the Sun in the summer than in the winter, but by the effects of Earth's 23.4-degree axial tilt. Each hemisphere is tilted towards the Sun in its respective summer, resulting in longer days and more perpendicular sunlight, with the opposite being true in the winter. Earth reaches the point in its orbit closest to the Sun in January, and it reaches the point farthest from the Sun in July, so the slight contribution of orbital eccentricity opposes the temperature trends of the seasons in the Northern Hemisphere. When a meteor or spacecraft enters the atmosphere, the heat of entry is not primarily caused by friction, but by adiabatic compression of air in front of the object. Egg balancing is possible on every day of the year, not just the vernal equinox. The Fisher Space Pen was not commissioned by NASA at a cost of millions of dollars, while the Soviets used pencils. Pencils posed a major risk to astronauts due to the release of substances such as shavings and pencil lead being a flight hazard. The pen was independently developed by Paul C. Fisher, founder of the Fisher Pen Company, with $1 million of his own funds (equivalent to $10 million in 2025). NASA tested and approved the pen for space use, then purchased 400 pens at $6 per pen (equivalent to $58 in 2025). The Soviet Union subsequently also purchased the Space Pen for its Soyuz spaceflights.
== Function == During swallowing, the soft palate and the uvula move together to close off the nasopharynx, and prevent food from entering the nasal cavity. It has also been proposed that the abundant amount of thin saliva produced by the uvula serves to keep the throat well lubricated. It has a function in speech as well. In many languages, a range of consonant sounds, known as uvular consonants, are articulated by creating a constriction of airflow between the uvula and the back of the tongue. The voiced uvular trill, written [ʀ] in the International Phonetic Alphabet, is one example; it is used in French, Arabic and Hebrew, among other languages. It has been suggested that the uvula is an accessory speech organ. Stimulation of the uvula also causes the gag reflex to initiate. This is often a problem for people with uvula piercings, and a common method of inducing vomiting. It also acts as a food sensor/guard that aids in breathing between mouthfuls, stopping small pieces of food from being inhaled, leading to choking.
To demonstrate just how deadly this species is, an estimate was made on the number of mice and adult human fatalities it is capable of causing in a single bite that yields the maximum dose of 400 mg. Based on the study by Ernst and Zug et al. 1996, which listed the LD50 of the coastal taipan at 0.106 mg SC and a venom yield of 400 mg, this would be sufficient to kill 208,019 mice and 59 adult humans in a single bite that delivers 400 mg of venom. The venom apparatus of this species is well developed. The fangs are the longest of any Australian elapid snake, being up to 1.2 cm (0.5 in) long, and are able to be brought forward slightly when a strike is contemplated. Coastal taipans can inject large amounts of highly toxic venom deep into the tissue. Its venom contains primarily taicatoxin, a highly potent neurotoxin known to cause hemolytic and coagulopathic reactions. The venom affects the nervous system and the blood's ability to clot, and bite victims may experience headache, nausea and vomiting, collapse, convulsions (especially in children), paralysis, internal bleeding, myolysis (destruction of muscle tissue) and kidney damage. In a single study done in Papua New Guinea, 166 patients with enzyme immunoassay-proven bites by Papuan taipans (Oxyuranus scutellatus canni) were studied in Port Moresby, Papua New Guinea. Of the 166 bite victims, 139 (84%) showed clinical evidence of envenoming: local signs were trivial, but the majority developed hemostatic disorders and neurotoxicity.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.